QS21-Initiated Fusion of Liposomal Small Unilamellar Vesicles to Form ALFQ Results in Concentration of Most of the Monophosphoryl Lipid A, QS21, and Cholesterol in Giant Unilamellar Vesicles

被引:2
作者
Abucayon, Erwin G. [1 ,2 ]
Rao, Mangala [1 ]
Matyas, Gary R. [1 ]
Alving, Carl R. [1 ]
机构
[1] Walter Reed Army Inst Res, US Mil HIV Res Program, 503 Robert Grant Ave, Silver Spring, MD 20910 USA
[2] Henry M Jackson Fdn Advancement Mil Med, 6720A Rockledge Dr, Bethesda, MD 20817 USA
关键词
giant unilamellar vesicle; vaccine adjuvant; monophosphoryl lipid A; cholesterol; QS21; QS-21; membrane fusion; liposome; BEHAVIOR; PH;
D O I
10.3390/pharmaceutics15092212
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Army Liposome Formulation with QS21 (ALFQ), a vaccine adjuvant preparation, comprises liposomes containing saturated phospholipids, with 55 mol% cholesterol relative to the phospholipids, and two adjuvants, monophosphoryl lipid A (MPLA) and QS21 saponin. A unique feature of ALFQ is the formation of giant unilamellar vesicles (GUVs) having diameters >1.0 mu m, due to a remarkable fusion event initiated during the addition of QS21 to nanoliposomes containing MPLA and 55 mol% cholesterol relative to the total phospholipids. This results in a polydisperse size distribution of ALFQ particles, with diameters ranging from similar to 50 nm to similar to 30,000 nm. The purpose of this work was to gain insights into the unique fusion reaction of nanovesicles leading to GUVs induced by QS21. This fusion reaction was probed by comparing the lipid compositions and structures of vesicles purified from ALFQ, which were >1 mu m (i.e., GUVs) and the smaller vesicles with diameter <1 mu m. Here, we demonstrate that after differential centrifugation, cholesterol, MPLA, and QS21 in the liposomal phospholipid bilayers were present mainly in GUVs (in the pellet). Presumably, this occurred by rapid lateral diffusion during the transition from nanosize to microsize particles. While liposomal phospholipid recoveries by weight in the pellet and supernatant were 44% and 36%, respectively, higher percentages by weight of the cholesterol (similar to 88%), MPLA (94%), and QS21 (96%) were recovered in the pellet containing GUVs, and <= 10% of these individual liposomal constituents were recovered in the supernatant. Despite the polydispersity of ALFQ, most of the cholesterol, and almost all of the adjuvant molecules, were present in the GUVs. We hypothesize that the binding of QS21 to cholesterol caused new structural nanodomains, and subsequent interleaflet coupling in the lipid bilayer might have initiated the fusion process, leading to creation of GUVs. However, the polar regions of MPLA and QS21 together have a "sugar lawn" of ten sugars, the hydrophilicity of which might have provided a driving force for rapid lateral diffusion and concentration of the MPLA and QS21 in the GUVs.
引用
收藏
页数:13
相关论文
共 40 条
  • [1] A Liquid Chromatography High-Resolution Tandem Mass Spectrometry Method to Quantify QS-21 Adjuvant and Its Degradation Products in Liposomal Drug Formulations
    Abucayon, Erwin G.
    Barrientos, Rodell C.
    Torres, Oscar B.
    Sweeney, Scott
    Whalen, Connor
    Matyas, Gary R.
    [J]. ACS OMEGA, 2023, 8 (23): : 21016 - 21025
  • [2] Formation of giant liposomes promoted by divalent cations: Critical role of electrostatic repulsion
    Akashi, K
    Miyata, H
    Itoh, H
    Kinosita, K
    [J]. BIOPHYSICAL JOURNAL, 1998, 74 (06) : 2973 - 2982
  • [3] Similarities and differences of chemical compositions and physical and functional properties of adjuvant system 01 and army liposome formulation with QS21
    Alving, Carl R. R.
    Rao, Mangala
    Matyas, Gary R. R.
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [4] [Anonymous], SAFETY TOLERABILITY
  • [5] [Anonymous], A Trial for the Study of Falciparum Malaria Protein 013 Administered via Intramuscular Injection in Healthy Adults, clinicaltrials.gov ID NCT04268420
  • [6] [Anonymous], Safety and immunogenicity Study of 2019-nCoV vaccine (mRNA-1273) for prophylaxis of SARS-CoV-2 Infection (COVID-19)
  • [7] [Anonymous], SARS COV 2 SPIKE FER
  • [8] [Anonymous], HIV Vaccine in HIV-uninfected Adults (RV546), clinicaltrials.gov ID NCT04658667
  • [9] [Anonymous], Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission (RV582), clinicaltrials.gov ID NCT05769569
  • [10] LIPOSOMES AS VACCINE CARRIERS - INCORPORATION OF SOLUBLE AND PARTICULATE ANTIGENS IN GIANT VESICLES
    ANTIMISIARIS, SG
    JAYASEKERA, P
    GREGORIADIS, G
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1993, 166 (02) : 271 - 280